The aim of this study was to evaluate the efficacy and tolerability of open-label lacosamide in patients with refractory sleep-related hypermotor epilepsy. The study was a case review of eight patients with refractory sleep-related hypermotor epilepsy treated with lacosamide. Seizure diaries compared the mean baseline seizure frequency with the most recent 3 months of follow-up. Five (62.5%) patients were responders, defined as ≥50% reduction in seizure frequency, over a mean duration of exposure of 21.5 months. The mean maintenance dose of lacosamide was 400 mg/day. No-one reported worsening of seizures. Lacosamide was well tolerated with initial fatigue being the main side-effect. Lacosamide is a potentially efficacious adjunctive therapy in patients with refractory sleep-related hypermotor epilepsy. A double-blind placebo-controlled study would determine its efficacy.
| INTRODUCTION
Sleep-related hypermotor epilepsy (SHE), previously nocturnal frontal lobe epilepsy, is a sleep-related disorder characterised by clusters of motor seizures during sleep. The disorder was renamed SHE to recognise the pattern of seizures (occurring during day and nighttime sleep), their localisation (which may be extra-frontal) and their motor manifestations (Tinuper et al., 2016) . Seizures may vary, from brief paroxysmal arousals to paroxysmal dystonia and hypermotor phenomena (Provini et al., 1999) . SHE varies markedly in severity and pharmacoresponsiveness; patients typically experience many seizures a night.
Seizures typically respond to carbamazepine (Scheffer et al., 1995) , although a third of patients are refractory (Oldani et al., 1998; Provini et al., 1999) . Because patients are often non-lesional, without localising abnormalities on electroencephalogram (EEG) or structural magnetic resonance imaging (MRI; Provini et al., 1999; Scheffer et al., 1995) , novel pharmacotheraputic options are required.
Lacosamide is an antiepileptic drug (AED) licensed for focal seizures. It was reported as efficacious in two patients with SHE (Liguori et al., 2016) . We also observed a marked response to lacosamide in one patient with SHE, which led us to review our experience of lacosamide as adjunctive treatment in eight patients with SHE. Patients were reviewed at regular intervals in the clinic. Seizure frequency was serially documented in seizure diaries. Where patients had not been reviewed in the previous 3 months at the time of study, telephone consultations were performed to ascertain current seizure frequency.
| MATERIALS AND METHODS
Treatment outcomes with lacosamide were defined as follows:
Responder: ≥50% reduction in seizure frequency (last 3 months of follow-up compared with the 3 months pretreatment).
Partial responder: 25%-50% reduction.
Non-responder: no change or increase in seizure frequency.
| Molecular analysis
All patients underwent sequencing of CHRNA4 and CHRNB2, the genes encoding the a4 and b2 subunits of the neuronal nicotinic acetylcholine receptor, as previously described (Phillips et al., 1998 (Phillips et al., , 2001 Steinlein et al., 1995) . Patients 2, 4, 5, 6 and 7 were also sequenced for the sodium-gated potassium channel gene KCNT1 associated with severe autosomal dominant SHE (Heron et al., 2012) . Patient 3 underwent whole-exome sequencing, which lead to the identification of a KCNT1 mutation (Heron et al., 2012 ).
All patients, or their parents or legal guardians in the case of minors or those with intellectual disability, gave informed research consent.
| RESULTS
The eight patients (five males) had a mean age of 36 years (range 21-54 years; Table 1 ). The mean age at seizure onset was 9 years (range 1-25 years). Three patients had intellectual disability and psychiatric features of psychosis (2) and autism spectrum disorder (2).
Patients experienced a range of sleep-related seizure phenomena, including stereotyped arousals and more prolonged hypermotor attacks, occurring both during daytime naps and night-time sleep.
Prior to lacosamide, all patients received a minimum of six AEDs, including carbamazepine. Whilst taking lacosamide, five patients continued with additional AEDs (Table 1 ). The mean length of exposure to lacosamide was 21.5 months (range 6-37 months); mean maintenance dose of 400 mg/day (range 300-600 mg/day). During the period of exposure to lacosamide, all doses of other AEDs remained unchanged. Of the six patients who responded to lacosamide, five were responders, defined as a >50% seizure reduction, and one (Patient 3) showed a 25% response (Table 1) 
| DISCUSSION
Refractory SHE is challenging to manage despite an increasing armamentarium of AEDs. SHE has a major impact on the lives of patients and their families, with poor sleep having a major impact on their quality of life (Provini, Bisulli, & Tinuper, 2012 Six-month follow-up. management is AED therapy. Here we show in a small retrospective observational series that lacosamide was effective in five out of eight patients. This was a highly refractory population who had failed six prior AEDs at least, including first-line agents such as carbamazepine.
The gold-standard in AED trials is a randomised double-blind placebo-controlled trial. For lacosamide, these show a 40% responder rate in focal epilepsy and a 36%-40% median reduction in seizure frequency when used as adjunctive therapy at doses of 200-600 mg/day (Ben-Menachem et al., 2007; Flores et al., 2012; Weston, Shukralla, McKay, & Marson, 2015) . No studies to date have examined the efficacy of lacosamide in SHE specifically, although two cases were reported showing dramatic reduction in seizure frequency following the introduction of lacosamide, and seizure freedom at 12 months with lacosamide monotherapy (Liguori et al., 2016) .
| Limitations
Our study strengthens the case for the use of lacosamide in SHE.
The results need to be interpreted in the context of the limited sample size and the inherent difficulty in obtaining accurate longterm data regarding seizure frequency in this population; many seizures are subtle and escape detection without video-EEG monitoring (Provini et al., 2012) . Three of our patients had a long-term bed partner. Diaries recorded by the remaining five patients and their carers are likely to be a conservative estimate of seizure frequency, as many more seizures were captured during video-EEG monitoring. Serial video-EEG monitoring would have been preferable, nevertheless seizure diaries remain the most practical way of monitoring seizure frequency. Data collection was undertaken for 3 months, as this was considered to be a reasonable time frame during which a sustained change in seizure frequency could be captured.
Five patients received lacosamide with carbamazepine or oxcarbazepine (Table 1) . Lacosamide, then licensed for use as adjunctive therapy in focal epilepsy, was only used as monotherapy in those patients participating in a clinical trial. Limited data have suggested that efficacy and adverse event rate are improved if lacosamide is combined with a non-sodium channel blocker AED (Villanueva et al., 2012) . A recent study of lacosamide in temporal lobe epilepsy did not reflect this (Borz ı et al., 2016) . Our numbers are too small to draw conclusions regarding the optimal combination of AEDs.
This case series adds support to a recent study of two cases of SHE who benefited from lacosamide. There is a need for randomised placebo-controlled studies to determine if lacosamide is indicated for specific syndromes, such as SHE.
